![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 31, 29307-29312, August 3, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas 77555-0643
Received for publication, April 26, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Upon physiological stress, families of stress
response genes are activated as natural defense mechanisms. Here, we
show that induction of specific inflammatory genes is significantly
dysregulated and altered in the heart of aged (24-26-month-old)
versus young (4-month-old) mice experimentally challenged
with a bacterial endotoxin, lipopolysaccharide (LPS, 1.5 mg/kg of body
mass). Whereas the LPS-mediated induction of cardiac mRNA
for tumor necrosis factor Bacterial infection triggers cascades of inflammatory responses,
which involve activation of various inflammatory mediators including
cytokines, growth factors, and cell adhesion molecules. Although these
inflammatory mediators act primarily for the host defense, they also
cause pathophysiological conditions characteristic of sepsis. Upon
infection with Gram-negative bacteria, released endotoxin
(e.g. lipopolysaccharide,
LPS)1 stimulates
monocytes/macrophages to produce such initial proinflammatory cytokines
as tumor necrosis factor IL-6, a multifunctional cytokine produced by a variety of cells, is
known to play important roles in immunological/inflammatory responses,
hematopoiesis (7), and synthesis of liver acute phase proteins (8).
High levels of IL-6 appear to have deleterious effects during systemic
inflammation, because a reduced endotoxic mortality rate was observed
in mice after treatment with anti-IL6 antibodies (9). IL-6 is also
known to exert a negative inotropic effect on myocardial tissues (10,
11). We have recently demonstrated that intraperitoneal injection of
young mice with LPS results in a rapid induction of mRNA for
IL-1 Aging is characterized by an altered immune function and stress
response (13, 14). Cardiovascular function during stress also declines
with aging (15). Thus, we hypothesized that induction of stress
response genes in the heart may be altered with aging. In the present
study, we show that LPS-induced expression of specific genes, including
those for IL-1 Animals--
Male C57BL/6, BALB/c, and CB6F1 mice were obtained
from colonies of the National Institute on Aging through Charles River Laboratories (Wilmington, MA). The newly arrived animals were kept at
least 10 days in a 12/12 h light/dark cycle and fed a standard chow
diet ad libitum before experiments. Mice were injected intraperitoneally with LPS (derived from Pseudomonas
aeruginosa, Sigma) at a dose of 1.5 µg/g of body mass. In
some experiments, in which young and aged mice did not show a
significant difference in their body masses, all mice were injected
with the same amount of LPS (50 µg, equivalent to ~1.5 µg/g of
body mass). After injection, animals, together with control
non-injected mice, were sacrificed by cervical dislocation at the
indicated time points, and tissues were quickly dissected. At the same
time, other major organs including brain, lung, liver, kidney, spleen,
and intestines were harvested and examined. Mice that exhibited any
signs of abnormality, such as injury and tumor, were eliminated from
the experiments. These procedures were approved by the University of
Texas Medical Branch Institutional Animal Care and Use Committee.
RNA Isolation and Hybridization Analyses--
Total RNA was
isolated using guanidine/phenol, and Northern blot hybridization was
performed as described previously (12). Slot blot hybridization
analysis for the IL-6 mRNA was performed using a Manifold II slot
blot apparatus (Schleicher & Schuell) with the same hybridization
condition as Northern blot analysis.
Protein Extraction and Enzyme-linked Immunosorbent
Assay--
Cytoplasmic proteins were extracted from mouse hearts as
described previously (12). The cytokine concentrations were determined by enzyme-linked immunosorbent assays using a commercial kit specific for mouse IL-1 Immunohistochemistry--
Cryo-sections of mouse hearts were
incubated overnight at 4 °C with polyclonal rabbit anti-rat IL-6
antibody SC-1267 (Santa Cruz Biotechnology, Santa Cruz, CA). After
serial washings with phosphate-buffered saline, the slides were
incubated with biotinylated secondary antibody for 45 min at room
temperature. The sections were developed with ABC reagent (ABC kit,
Vector Laboratories, Burlingame, CA) for 45 min. After incubation in
Fast Red (Sigma, F-4648) containing 1 mM levamisole, the
slides were mounted for light microscopy (12).
Age-associated Differential Induction of Specific Inflammatory
Genes in Mouse Hearts during Endotoxic Stress--
To determine
whether cardiovascular gene expression during the inflammatory response
is altered by aging, we compared the endotoxin-mediated induction of
mRNAs for several inflammatory genes in the hearts of young
(4-month-old) versus aged (24-month-old) C57BL/6 mice. Mice
were injected with 50µg of LPS, and sacrificed at 1, 3, 6, 12, and 24 h thereafter together with control non-injected mice (four mice per
time point). During these experiments, we confirmed the previously
reported higher mortality rate in aged mice by endotoxic stress (16,
17). Approximately 10% of aged mice died within 24 h after LPS
injection, whereas no young mice died during the same time period.
We analyzed the RNA from the hearts by Northern blot hybridization and
examined the induction of inflammatory genes, including IL-1 Prolonged Induction of the IL-6 mRNA in Aged Mouse Hearts
during Endotoxic Stress--
The high levels of IL-6 mRNA observed
in the aged mice may be caused by a prolonged induction of the gene in
all aged mice or possibly by the inclusion of one aged mouse or a few
aged mice that were induced to produce exceptionally high levels of
IL-6 mRNA. To distinguish these possibilities, we measured the IL-6 mRNA level in each individual young or aged mouse throughout the time course. As shown in Fig. 1, B and C,
induction of IL-6 mRNA in young hearts consistently occurred at
3 h after LPS injection, and the mRNA levels came back to near
the undetectable basal level by 6 h. The standard deviations for
the young mice were small at all time points, suggesting that induction
of the IL-6 gene in the heart is tightly regulated in young animals. On
the other hand, the IL-6 mRNA induction varied substantially among
individual aged mice, suggesting that induction of the IL-6 gene is
dysregulated in aged hearts. At 3 h after LPS injection, the IL-6
mRNA was induced very strongly in one aged mouse and was not
induced at all in two others, suggesting that the IL-6 induction in
response to LPS can be augmented or delayed in some aged mice. From 6 to 12 h after LPS injection, all the aged mice showed high levels of induced IL-6 mRNA, equivalent to the average peak level in young
mice. Even at 24 h post-injection, high levels of the IL-6 mRNA were still detected in some of the aged mice. Because
persistently high levels of IL-6 mRNA were commonly seen in aged
mice, we concluded that induction of the cardiac IL-6 mRNA in
response to endotoxic shock is prolonged in aged animals.
The Augmented Induction of Cardiac IL-6 mRNA in Aged Mice of
Different Strains--
To determine whether the age-associated
differential induction of IL-6 mRNA is specific to the C57BL/6
mouse or is common among other strains, we conducted similar
experiments using three different mouse strains, C57BL/6,
BALB/c, and their hybrid CB6. For this experiment, we compared the
induced IL-6 mRNA levels in the hearts of young (4-7-month-old)
versus aged (24-28-month-old) mice 6 h after LPS
injection (n = 4). We chose this time point because it
was a time where IL-6 mRNA levels differ significantly in young and
aged C57BL/6 mice. As demonstrated in Fig.
2, the LPS-induced IL-6 mRNA levels
were significantly higher than those in young hearts, not only in
C57BL/6 mice but also in BALB/c and CB6 mice. These results suggest
that the age-associated extended induction of the IL-6 gene in response
to LPS is not mouse strain-specific.
The Augmented Induction of Cardiac IL-6 mRNA during the Aging
Process--
We sought to determine at what age the endotoxin-mediated
induction of the cardiac IL-6 changes, i.e. whether this is
a gradual change or one that occurs at a specific age. We compared the
cardiac IL-6 mRNA levels at 6 h post-LPS injection among four
different age groups: 4-, 10-, 16-17-, and 23-27-month old
(n = 6-8 per group). As shown in Fig.
3, the age-associated overexpression of
the IL-6 gene occurred in some mice by the age of 10 months, became
significant at age 16-17 months, and was even more dramatic at 23 months and later. Statistically significant differences were found
between the 4- and 23-27-month-old groups (p < 0.001) and also between the 4- and 16-17-month-old groups (p < 0.01) but not between the 4- and 10-month-old groups
(p > 0.3). Thus, we conclude that the age-associated
elevation of IL-6 gene induction is not evident until at least 10 months of age, but it occurs by 16 months of age and becomes greater
with increasing age.
Augmented Induction of Cardiac IL-6 Protein by Aging--
In these
experiments we used enzyme-linked immunosorbent assay to compare the
cytokine protein levels in the hearts of young versus aged
mice that were injected with 50 µg of LPS and sacrificed at 1, 3, 6, 12, and 24 h thereafter, together with control non-injected mice
(three to six mice per time point). The IL-6 levels at 0 and 1 h
were ~20 pg/mg of protein or less in both young and aged mice. In
young mice, a rapid increase and subsequent decline in the cardiac IL-6
protein levels were seen at 3 and 6 h, respectively, demonstrating
that the induction of IL-6 protein synthesis follows the pattern of
induced mRNA levels (see Figs. 1A and 4). The average IL-6 protein levels in the aged hearts were 7.5-35-fold higher than
those in the young hearts from 3 to 24 h after LPS injection. All
the aged mice showed higher cardiac IL-6 levels than the young mice
from 3 to 12 h after LPS injection. Even 24 h after LPS
injection, one of the aged mice still showed a higher IL-6 level than
the average peak IL-6 level (at 3 h) in young mice. Using the same protein samples, we also measured IL-1
The data for these two proteins also agree with the mRNA data (Fig.
1) that IL-1 Localization of Cardiac IL-6 to Microvascular Walls--
We
performed immunohistochemical analyses to localize IL-6 in the young
and aged mouse hearts during endotoxic stress. Young (4-month-old) and
aged (26-month-old) C57BL/6 mice were injected with LPS (1.5 µg/g of
body mass) and sacrificed 6 h later, and frozen heart sections
were prepared. Immunohistochemical analyses using anti-IL-6 antibody
detected IL-6 mostly in nonmyocardial cells, particularly in the
microvascular walls of hearts from both young and aged mice, suggesting
that IL-6 is expressed mostly in vascular endothelial cells (Fig.
5, A and B). IL-6
was also detected in relatively large vessels in both young and aged
mice (Fig. 5C) and in a small number of myocardial cells
only in aged mice (Fig. 5B).
In the present study, we clearly demonstrated a significantly
elevated and prolonged induction of IL-6 in aged mouse hearts during
endotoxic stress. Induction of the IL-1 The augmented induction of the IL-6 gene may be due to an increased
transcriptional rate for the gene and/or a decreased rate of its
mRNA degradation in aged tissues. The regulatory region of the IL-6
gene contains putative binding sites for such stress-activated transcription factors as nuclear factor Our results demonstrated that the age-associated overexpression of IL-6
in the heart occurs more dramatically at the protein level than at the
mRNA level. The age-associated increases in average peak levels (3 h after LPS injection) were ~1.5- and 10-fold at the mRNA and
protein levels, respectively (Figs. 1C and 4). The
difference in the magnitude of increase between the mRNA and protein levels raises the possibility that either the translational rate or protein stability of IL-6 is increased in the aged mouse heart.
Whereas the IL-6 mRNA is solely derived from cardiac expression, the IL-6 protein may be produced in other tissues and reach the heart
via the circulation. Indeed, the activity of plasma IL-6 after
injection with LPS was reportedly higher in aged rats than in young
rats (22). Thus, although we have recently shown that the heart induces
the highest level of IL-6 mRNA among all major tissues in young
mice during endotoxic stress (12), extra-cardiac tissues may also show
profound age-associated overexpression of IL-6 as well.
Our previous study using in situ hybridization and
in vitro cell cultures demonstrated that cardiac IL-6 is
expressed mainly by nonmyocardial cells via IL-1 The role of IL-6 during systemic inflammation is complex. An
early study demonstrated a reduced LPS-induced mortality rate in mice
treated with anti-IL-6 antibodies, clearly suggesting that a high level
of IL-6 is harmful during endotoxic shock (9). However, a more recent
study showed a somewhat elevated LPS-induced mortality rate in IL-6
( The elderly show a significantly elevated mortality rate during
septic shock after bacterial infection. Although the precise mechanisms
for this increase in susceptibility to sepsis are largely unknown,
mortality in elderly septic patients often depends on the physiological
reserve and stress tolerance of the cardiovascular and pulmonary
systems (34, 35). During sepsis, cascades of inflammatory response
mediate various cardiovascular dysfunctions, including vascular
endothelial cell damage, vascular permeabilization, vasodilatation,
hypotension, and myocardial depression (36). Persistently high levels
of serum IL-6 reportedly predict high mortality in septic patients (1,
37-39). Therefore, augmented induction of IL-1 IL-6 forms a complex with its specific receptor and a membrane
glycoprotein (gp130) to exert its activity through two known signal
pathways; one activates the transcription factor STAT3 via the
Janus tyrosine kinases, and the other activates NF/IL6 (or
CAAT/enhancer-binding protein) transcription factors via Ras and
mitogen-activated protein kinase. Several stress response genes are
induced by IL-6 via these gp130 pathways (41, 42). Therefore,
overexpression of IL-6 in aged cardiovascular tissues may result in
overexpression of various stress response genes. Identification of such
stress response genes should provide important information on altered
biochemical mechanisms in aged animals in response to endotoxic stress.
In conclusion, IL-6 is strongly induced in the heart, mostly in the
microvascular walls, during endotoxic stress, and this induction is
significantly augmented and prolonged with aging. The cardiac gene
expression of IL-1
or inducible nitric-oxide synthase
showed no age-associated differences, the induction of interleukin-1
(IL-1
) and intracellular adhesion molecule-1 was modestly extended
with aging, and the induction of IL-6 was significantly prolonged with
aging. This age-associated phenomenon occurred gradually from 4 to 17 months of age and became more evident after 23 months of age. The
age-associated augmentation of the cardiac IL-6 induction was also
dramatic at the protein level. Immunohistochemically, the LPS-induced
cardiac IL-6 was localized mainly in the microvascular walls. Aged but not young mice showed a high mortality rate during these experiments. These results demonstrate that endotoxin-mediated induction of specific
inflammatory genes in cardiovascular tissues is altered with aging,
which may be causally related to the increased susceptibility of aged
animals to endotoxic stress.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(TNF
) and interleukin 1
(IL-1
).
These two in turn elicit a subsequent release of secondary inflammatory
mediators, including inducible nitric-oxide synthase (iNOS),
intracellular adhesion molecule-1 (ICAM-1), and IL-6 (1). TNF
is
known to function synergistically with IL-1
to cause myocardial
depression during acute septic shock (2). Induction of iNOS and
subsequent production of nitric oxide are known to be important
mediators for systemic vasodilatation and hypotension during septic
shock (3). ICAM-1 promotes neutrophil-myocardial or neutrophil-vascular
endothelial cell adhesion, which causes cardiovascular tissue injury
due to the cytotoxic activity of neutrophils (4-6).
and TNF
, followed by a strong induction of IL-6 and ICAM-1
in the heart. The IL-6 induction in the heart was more intense than in
any other tissue examined, including brain, lung, liver, kidney,
spleen, and skeletal muscle (12).
, ICAM-1, and IL-6 in particular, is
significantly prolonged and augmented in the hearts of aged mice
compared with young mice. We also show that the endotoxin-induced cardiac IL-6 is mainly localized to microvascular walls in the heart.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, TNF
, and IL-6 (Endogen, Inc., Woburn, MA). The detection limits of this kit were 3, 10, and 7 pg/ml, respectively.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
,
TNF
, IL-6, ICAM-1, and iNOS. As shown in Fig.
1, the IL-1
and TNF
mRNA levels
peaked at 1 h, the ICAM-1 and IL-6 mRNA levels peaked at
3 h, and the iNOS mRNA levels peaked at 6 h
post-injection in both young and aged mice. The kinetics confirmed that
the two early inflammatory genes, IL-1
and TNF
, are induced
before the secondary inflammatory mediator genes, ICAM-1, IL-6, and
iNOS, in the heart. Whereas the TNF
and iNOS mRNA levels did not
show significant age-associated differences, the induced IL-6 mRNA levels after the peak time point were significantly higher in aged mice
than in young mice. There was also an age-associated elevation in
IL-1
and ICAM-1 mRNA levels at certain time points, although not
to the same extent as in IL-6. These results demonstrate that aging
alters the induction patterns of specific inflammatory genes in the
heart during endotoxic stress.

View larger version (55K):
[in a new window]
Fig. 1.
RNA blot analyses demonstrating that specific
genes are differentially induced in young versus aged
mouse hearts after LPS injection. Young (4-month-old) and aged
(24-month-old) C57BL/6 mice were injected with 50 µg of LPS and
sacrificed at the indicated time points. Total RNA was isolated from
the hearts and subjected to Northern or slot blot hybridization
analyses using a mouse cDNA for each gene as a probe. Ribosomal 18 S RNA was also measured for normalization. A, Northern blot
analyses on total heart RNA. Each lane contained 20 µg of RNA derived
equally from four individual mice. B, slot blot
hybridization analysis to measure the IL-6 mRNA level in each RNA
sample used for A. Each slot contained 5 µg of the RNA
from an individual mouse. C, densitometric analysis of the
IL-6 expression detected in B. The average value of the
mRNA levels of young mice at peak induction (3 h) was set at 1. Error bars represent the S.D. In young mice, the S.D. values were so
small that some error bars are not visible. ** indicates
p < 0.01 with Student's t test of the 4- and 24-month-old mice for each time point. D,
densitometric analyses of the expression of the other four genes
detected in A. The peak mRNA level in young mice was set
at 1 for each graph.

View larger version (53K):
[in a new window]
Fig. 2.
Northern blot analyses demonstrating
age-augmented induction of cardiac IL-6 mRNA after LPS injection in
a mouse strain-independent fashion. Young (4-7-month-old) and
aged (24-28-month-old) mice were injected with 50 µg (or 1.5 µg/g
of body mass; intraperitoneal) of LPS and sacrificed 6 h later.
Total RNA was isolated from the hearts and subjected to Northern
analysis using a mouse IL-6 cDNA as a probe. A probe for 18 S rRNA
was also used as a control. Each lane contains pooled RNA isolated from
four individual mouse hearts, with strain and age indicated in the
figure.

View larger version (42K):
[in a new window]
Fig. 3.
Northern blot analyses demonstrating that
cardiac IL-6 mRNA induction is gradually augmented during
aging. CB6 mice at various ages (4 months, n = 8;
10 months, n = 8; 16-17 months, n = 7;
and 23-27 months, n = 6) were injected with LPS (1.5 µg/g of body mass; intraperitoneal) and sacrificed 6 h later.
Total RNA was isolated from the hearts and subjected to Northern
analysis using a mouse IL-6 cDNA as a probe. A probe for 18 S rRNA
was also measured as a control for normalization. A,
autoradiogram. B, densitometric analyses. Each triangle
represents the IL-6 mRNA level of an individual mouse. The average
mRNA level of the 4-month-old group was set at 1; the average
mRNA level in each age group is indicated by a horizontal
line. Student's t test was performed between the
4-month-old group and other age groups. ** and *** indicate
p < 0.01 and 0.001, respectively.
and TNF
levels in young versus aged mice hearts. IL-1
induction was modestly
elevated in aged mice compared with young mice (2.2-fold elevation at
the peak level; Fig. 4B), but
TNF
induction did not show any difference in young versus
aged mice (data not shown).

View larger version (17K):
[in a new window]
Fig. 4.
Cytokine protein levels in hearts from young
versus aged mice after LPS administration. Young
(4-month-old) and aged (24-26-month-old) C57BL/6 mice were injected
with 50 µg of LPS and sacrificed at the indicated time points (three
to six mice per time point in each age group). The cytoplasmic protein
fraction was isolated from the hearts of individual mice, and the
concentrations of IL-6 (A) and IL-1
(B) were
measured by enzyme-linked immunosorbent assay. Error bars represent the
S.D. In young mice, the S.D. values were so small that some error bars
are not visible. Student's t test was performed between the
young and aged groups. *, **, and *** indicate p < 0.05, 0.01, and 0.001, respectively.
showed moderate age-associated elevation whereas TNF
induction was not affected by aging. These results demonstrate that,
during endotoxic stress, the age-associated overexpression of specific
inflammatory cytokines occurs not only at the mRNA level but also
at the protein level.

View larger version (132K):
[in a new window]
Fig. 5.
Immunohistochemical localization of
IL-6 in the hearts. IL-6 was detected in heart sections from
C57BL/6 mice 6 h after treatment with LPS (1.5 µg/g of body
mass; intraperitoneal). A, IL-6 localized to microvascular
walls of a 4-month-old mouse (open arrows). B,
IL-6 localized to microvascular walls (open arrows) and
myocardium (filled arrowheads) of a 26-month-old mouse.
C, IL-6 localized to a relatively larger vessel of a
4-month-old mouse. Black bars represent 100 µm.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and ICAM-1 genes was also
elevated or extended in the aged mice, although the extent was not as
dramatic as for IL-6. IL-1
is an important inducer of both IL-6 and
ICAM-1 (4, 12); so the elevated IL-1
expression may be responsible
for the prolonged induction of the ICAM-1 gene in aged mice. However,
the moderate elevation of IL-1
expression alone cannot explain the
dramatic overexpression of IL-6 in the aged mice. Because the
LPS-mediated induction of a subset of inflammatory genes was altered in
aged mice, we propose that the augmented induction of these genes
probably is not caused by a decreased rate of clearance of
endotoxin from aged animals.
B and nuclear factor/IL-6 (NF/IL6) (17) whose DNA binding activities increase with aging in mouse heart and liver, respectively (18, 19). Such an age-related increase in the activation of transcription factors may enhance the
transcriptional rate of the IL-6 gene and increase pool levels for its
mRNA. On the other hand, there have been studies suggesting that
the expression of several inflammatory genes is regulated by mRNA
stability and that the stabilization is altered by aging and
inflammatory signals (20, 21). It is yet to be determined whether
stability of the IL-6 mRNA in the cardiovascular tissues increases
with age.
action during
endotoxic stress. In that study, we could not identify which
nonmyocardial cells (i.e. fibroblasts, macrophages, vascular
endothelial cells, or smooth muscle cells) express IL-6 (12). In the
present study, we found that cardiac IL-6 was mostly localized to
microvascular walls, suggesting that microvascular endothelial cells
are the major cell source of IL-6 produced during endotoxic stress. It has been demonstrated that cultured human endothelial cells express IL-6 strongly in response to IL-1
(23). Because IL-6 was also identified in relatively large vascular tissues, vascular smooth muscle
cells may also express IL-6. According to previous in vitro studies, macrophage cultures from the elderly produced less IL-6 than
those from young subjects in response to LPS treatment (24), whereas
whole aorta cultures from aged rats produced more IL-6 than those from
young rats after LPS treatment (25). Therefore, vascular endothelial
and smooth muscle cells are probably the major cells that overproduce
IL-6 in the aged heart during endotoxic stress. Interestingly, IL-6
expression was detected in a small population of myocardial cells from
LPS-treated aged, but not young, mice. This myocardial cell-derived
IL-6 in aged mouse hearts may be attributed at least partly to the
age-associated overproduction of cardiac IL-6. Because myocardial cells
reportedly express IL-6 in vitro under hypoxic conditions
(26), the IL-6 detected in myocardium of aged mice may be an indication
of tissue ischemia during endotoxic shock.
/
) knockout mice, suggesting that IL-6 may also have a beneficial
role during endotoxic shock (27). Indeed, as we have recently shown,
IL-6 may have a self-regulatory function to suppress its own inducers
(TNF
and IL-1
) in the heart during endotoxic stress (12). IL-6 is
a multifunctional cytokine and is often considered "a double-edged
sword." Upon physiological stress such as infection, an appropriate
(and probably beneficial) amount of IL-6 is rapidly produced and
presumably functions to protect tissues. As seen in Fig. 1, such
induction is tightly regulated and does not last long in healthy young
animals. On the other hand, uncontrolled overexpression of IL-6 is
obviously harmful, because various transgenic mouse models
overexpressing IL-6 develop various pathologies, including
plasmacytosis (28), adrenal hyperplasia (29), cardiac hypertrophy (30),
muscle atrophy (31), and growth retardation (32); this variety possibly results from the different tissues and levels of overexpression and
the tissue distribution pattern of the IL-6 receptor. ICAM-1 promotes neutrophil-myocyte adhesion (5), and IL-6 stimulates neutrophils to produce hydrogen peroxide (33). Thus, overproduction of
ICAM-1 and IL-6 in aged tissues during inflammation may cause elevated
activation of neutrophils and resulting oxidative stress, which may
lead to cardiovascular cell injury. In our study, mice were treated
with a single LPS injection. However, in clinical septic conditions
during infection, LPS is released continuously; so the duration of
overexpression of these genes and resulting effects in aged animals may
be far greater than that observed in our experimental model.
, IL-6, and ICAM-1 in
aged mouse hearts may be causally associated with the high mortality
rate of aged mice during endotoxic stress. Endotoxin-mediated induction
of TNF
and nitric oxide in plasma was reportedly increased modestly
by aging (2-fold and 26%, respectively), and pretreatment with
anti-TNF
antibody reduced LPS mortality rate in both young and aged
mice, suggesting that TNF
has an important role in LPS mortality
(40). However, because LPS-mediated induction of TNF
and iNOS in the heart was not affected by aging, they may not be the primary factors contributing to the age-associated cardiovascular dysfunction and high
mortality during systemic inflammation.
and ICAM-1 is also elevated or extended with
aging during endotoxic stress. We propose such increased intensity
and/or duration of the expression of inflammatory genes as important
characteristics of aging that may be causally associated with the
elevated susceptibility in aged subjects to inflammatory stress.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Drs. M. S. Runge, C. Patterson, S. Waxman, Z. Hu, and S. Yamamoto for immunohistochemical studies. We also thank Drs. D. A. Konkel and S. Yamamoto for critically reading the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by Grant-in-aid 97G-654 from the American Heart Association, Texas Affiliate, a Seed Money grant from the University of Texas Medical Branch Sealy Center on Aging (to H. S.), and Grant 2-P01-AG10514 from the NIA, National Institutes of Health (to J. P.; publication number 114).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Human
Biological Chemistry and Genetics, University of Texas Medical Branch,
301 University Boulevard, Galveston, TX 77555-0643. Tel.: 409-772-2761; Fax: 409-772-9216; E-mail: jpapacon@utmb.edu.
Published, JBC Papers in Press, May 29, 2001, DOI 10.1074/jbc.M103740200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
LPS, lipopolysaccharide;
TNF
, tumor necrosis factor
;
IL, interleukin;
iNOS, inducible nitric-oxide synthase;
ICAM-1, intracellular adhesion
molecule-1.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Lamy, M., and Deby-Dupont, G. (1995) Intensive Care Med. 21 Suppl. 2, 250-257 |
| 2. | Kumar, A., Thota, V., Dee, L., Olson, J., Uretz, E., and Parrillo, J. E. (1996) J. Exp. Med. 183, 949-958 |
| 3. | Grocott-Mason, R. M., and Shah, A. M. (1998) Intensive Care Med. 24, 286-295 |
| 4. | Smith, C. W., Entman, M. L., Lane, C. L., Beaudet, A. L., Ty, T. I., Youker, K., Hawkins, H. K., and Anderson, D. C. (1991) J. Clin. Invest. 88, 1216-1223 |
| 5. | Youker, K., Smith, C. W., Anderson, D. C., Miller, D., Michael, L. H., Rossen, R. D., and Entman, M. L. (1992) J. Clin. Invest. 89, 602-609 |
| 6. | Mantovani, A., Bussolino, F., and Dejana, E. (1992) FASEB J. 6, 2591-2599 |
| 7. | Akira, S., and Kishimoto, T. (1992) Immunol. Rev. 127, 25-50 |
| 8. | Castell, J. V., Gomez-Lechon, M. J., David, M., Andus, T., Geiger, T., Trullenque, R., Fabra, R., and Heinrich, P. C. (1989) FEBS Lett. 242, 237-239 |
| 9. | Starnes, H. F., Jr., Pearce, M. K., Tewari, A., Yim, J. H., Zou, J. C., and Abrams, J. S. (1990) J. Immunol. 145, 4185-4191 |
| 10. | Finkel, M. S., Oddis, C. V., Jacob, T. D., Watkins, S. C., Hattler, B. G., and Simmons, R. L. (1992) Science 257, 387-389 |
| 11. | Finkel, M. S., Hoffman, R. A., Shen, L., Oddis, C. V., Simmons, R. L., and Hattler, B. G. (1993) Am. J. Cardiol. 71, 1231-1232 |
| 12. | Saito, H., Patterson, C., Hu, Z., Runge, M. S., Tipnis, U., Sinha, M., and Papaconstantinou, J. (2000) Am. J. Physiol. 279, H2241-H2248 |
| 13. | Papaconstantinou, J., Reisner, P. D., Liu, L., and Kunninger, D. (1996) in Handbook of the Biology of Aging (Schneider, E. L. , and Rowe, J. W., eds), 4th Ed. , pp. 150-183, Academic Press, San Diego, CA |
| 14. | Miller, R. A. (1996) in Handbook of the Biology of Aging (Schneider, E. L. , and Rowe, J. W., eds), 4th Ed. , pp. 355-392, Academic Press, San Diego, CA |
| 15. | Lakatta, E. G. (1990) in Handbook of the Biology of Aging (Schneider, E. L. , and Rowe, J. W., eds), 3rd Ed. , pp. 181-218, Academic Press, San Diego, CA |
| 16. | Tateda, K., Matsumoto, T., Miyazaki, S., and Yamaguchi, K. (1996) Infect. Immun. 64, 769-774 |
| 17. | Tanabe, O., Akira, S., Kamiya, T., Wong, G. G., Hirano, T., and Kishimoto, T. (1988) J. Immunol. 141, 3875-3881 |
| 18. | Helenius, M., Hanninen, M., Lehtinen, S. K., and Salminen, A. (1996) J. Mol. Cell. Cardiol. 28, 487-498 |
| 19. | Hsieh, C. C., Xiong, W., Xie, Q., Rabek, J. P., Scott, S. G., An, M. R., Reisner, P. D., Kuninger, D. T., and Papaconstantinou, J. (1998) Mol. Biol. Cell 9, 1479-1494 |
| 20. | Kumar, S., Millis, A. J., and Baglioni, C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4683-4687 |
| 21. | Akashi, M., Loussararian, A. H., Adelman, D. C., Saito, M., and Koeffler, H. P. (1990) J. Clin. Invest. 85, 121-129 |
| 22. | Foster, K. D., Conn, C. A., and Kluger, M. J. (1992) Am. J. Physiol. 262, R211-R215 |
| 23. | Sironi, M., Breviario, F., Proserpio, P., Biondi, A., Vecchi, A., Van Damme, J., Dejana, E., and Mantovani, A. (1989) J. Immunol. 142, 549-553 |
| 24. | Delpedro, A. D., Barjavel, M. J., Mamdouh, Z., Faure, S., and Bakouche, O. (1998) J. Interferon Cytokine Res. 18, 429-437 |
| 25. | Belmin, J., Bernard, C., Corman, B., Merval, R., Esposito, B., and Tedgui, A. (1995) Am. J. Physiol. 268, H2288-H2293 |
| 26. | Yamauchi-Takihara, K., Ihara, Y., Ogata, A., Yoshizaki, K., Azuma, J., and Kishimoto, T. (1995) Circulation 91, 1520-1524 |
| 27. | Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X. F., and Achong, M. K. (1998) J. Clin. Invest. 101, 311-320 |
| 28. | Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., and Kishimoto, T. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7547-7551 |
| 29. | Raber, J., O'Shea, R. D., Bloom, F. E., and Campbell, I. L. (1997) J. Neurosci. 17, 9473-9480 |
| 30. | Hirota, H., Yoshida, K., Kishimoto, T., and Taga, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4862-4866 |
| 31. | Fujita, J., Tsujinaka, T., Ebisui, C., Yano, M., Shiozaki, H., Katsume, A., Ohsugi, Y., and Monden, M. (1996) Eur. Surg. Res. 28, 361-366 |
| 32. | De Benedetti, F., Alonzi, T., Moretta, A., Lazzaro, D., Costa, P., Poli, V., Martini, A., Ciliberto, G., and Fattori, E. (1997) J. Clin. Invest. 99, 643-650 |
| 33. | Yuan, L., Inoue, S., Saito, Y., and Nakajima, O. (1993) Exp. Cell Res. 209, 375-381 |
| 34. | Stengle, J., and Dries, D. (1994) Crit. Care Nurs. Clin. North Am. 6, 421-427 |
| 35. | Streat, S. J., Plank, L. D., and Hill, G. L. (2000) World J. Surg. 24, 655-663 |
| 36. | Baldwin, K. M., Davey, S. S., Morris, S. E., and Burger, M. (1998) in Pathophysiology: The Biologic Basis for Disease in Adults and Children (McCance, K. L. , and Huether, S. E., eds) , pp. 1570-1601, Mosby, Inc., St. Louis, MO |
| 37. | Thijs, L. G., and Hack, C. E. (1995) Intensive Care Med. 21 Suppl. 2, 258-263 |
| 38. | Damas, P., Ledoux, D., Nys, M., Vrindts, Y., De Groote, D., Franchimont, P., and Lamy, M. (1992) Ann. Surg. 215, 356-362 |
| 39. | Simpson, A. J., Smith, M. D., Weverling, G. J., Suputtamongkol, Y., Angus, B. J., Chaowagul, W., White, N. J., van Deventer, S. J., and Prins, J. M. (2000) J. Infect. Dis. 181, 621-625 |
| 40. | Chorinchath, B. B., Kong, L. Y., Mao, L., and McCallum, R. E. (1996) J. Immunol. 156, 1525-1530 |
| 41. | Kishimoto, T., Taga, T., and Akira, S. (1994) Cell 76, 253-262 |
| 42. | Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998) Biochem. J. 334, 297-314 |
This article has been cited by other articles:
![]() |
B. M. Meador, C. P. Krzyszton, R. W. Johnson, and K. A. Huey Effects of IL-10 and age on IL-6, IL-1{beta}, and TNF-{alpha} responses in mouse skeletal and cardiac muscle to an acute inflammatory insult J Appl Physiol, April 1, 2008; 104(4): 991 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, X. Chen, Q. Hong, H. Lin, H. Zhu, Q. Liu, J. Wang, Y. Xie, X. Shang, S. Shi, et al. TIMP-1 Promotes Age-Related Renal Fibrosis Through Upregulating ICAM-1 in Human TIMP-1 Transgenic Mice J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2006; 61(11): 1130 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Gorenne, M. Kavurma, S. Scott, and M. Bennett Vascular smooth muscle cell senescence in atherosclerosis Cardiovasc Res, October 1, 2006; 72(1): 9 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Matthews, I. Gorenne, S. Scott, N. Figg, P. Kirkpatrick, A. Ritchie, M. Goddard, and M. Bennett Vascular Smooth Muscle Cells Undergo Telomere-Based Senescence in Human Atherosclerosis: Effects of Telomerase and Oxidative Stress Circ. Res., July 21, 2006; 99(2): 156 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Acuna-Castillo, E. Leiva-Salcedo, C. R. Gomez, V. Perez, M. Li, C. Torres, R. Walter, D. M. Murasko, and F. Sierra T-kininogen: a biomarker of aging in fisher 344 rats with possible implications for the immune response. J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2006; 61(7): 641 - 649. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zou, S. Yoon, K. J. Jung, C. H. Kim, T. G. Son, M.-S. Kim, Y. J. Kim, J. Lee, B. P. Yu, and H. Y. Chung Upregulation of aortic adhesion molecules during aging. J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2006; 61(3): 232 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Hsieh and J. Papaconstantinou Thioredoxin-ASK1 complex levels regulate ROS-mediated p38 MAPK pathway activity in livers of aged and long-lived Snell dwarf mice FASEB J, February 1, 2006; 20(2): 259 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Park and T. A. Prolla Gene expression profiling studies of aging in cardiac and skeletal muscles Cardiovasc Res, May 1, 2005; 66(2): 205 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Edwards, D. Sarkar, R. Klopp, J. D. Morrow, R. Weindruch, and T. A. Prolla Age-related impairment of the transcriptional responses to oxidative stress in the mouse heart Physiol Genomics, April 16, 2003; 13(2): 119 - 127. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |